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Abstract
Background: Current testing of symptomatic patients for SARS-CoV-2 involves the use of 
nucleic acid amplification tests, also known as genetic, RNA or PCR to detect viral RNA. The 
initial use of point-of-care (POC) antibody tests, also known as serological tests in the manage-
ment of SARS-CoV-2 infection was limited. In this review, we determine the significance of POC 
antibody serological tests and explore their possible role in the diagnosis and management of 
patients infected with SARS-CoV-2 virus.
Methods: A literature search was conducted in Google Scholar, PubMed, and Embase, and 
supplemented by searching the Center for Disease Control (CDC), and the Infectious Diseases 
Society of America (IDSA) websites. We identified 7 articles published in the last 6 months per-
taining to the keywords. The sensitivity and specificity of the IgG/IgM antibody tests obtained 
from these studies were compared and used to determine the clinical importance of the rapid 
diagnostic antibody test in SARS-CoV-2 infection.
Results: Through the literature review, it was found that POC diagnostic antibody tests can 
be used as an adjuvant with the nucleic acid amplification tests in determining both active and 
post-exposure antibodies. These rapid antibody IgG/IgM tests had high sensitivity, the ability of 
a test to correctly identify those with the disease, and high specificity, the ability of the test to 
correctly identify those without the disease.
Conclusion: Emerging studies indicate the importance of POC antibody serological testing as 
an important diagnostic tool in the current SARS-CoV-2 pandemic. Considering the limitations 
of the molecular methods of testing, POC antibody tests can help reduce dependency on the 
molecular assays of testing when used in conjunction with them.
Introduction
IgG and IgM are among the different types of antibodies produced during an immuno-
logical response to a pathogen. Detection of IgM in the body indicates a recent infection 
while the presence of IgG indicates a prior exposure to the same pathogen or a chronic 
infection. The two major antigenic targets of severe acute respiratory syndrome corona-
virus 2 (SARS-CoV-2) virus against which antibodies are detected are spike glycoprotein 
(S) and nucleocapsid phosphoprotein (N). As per CDC, SARS-CoV-2 infection is unusual 
as there is simultaneous appearance of both IgG and IgM antibodies in the serum within 
2-3 weeks after the onset of illness. Therefore, detection of IgM without IgG is uncom-
mon during this timeframe. [1] Studies indicate that serological tests can detect the pres-
ence of SARs-CoV-2 IgG and IgM antibodies as early as day 4 after symptom onset, how-
ever, antibodies could be also be detected in the middle and later course of the disease. 
[2] Most patients seroconvert around 7-11 days post-exposure to the virus. [3] One study 
found that the IgM antibodies initially increased followed by a decline while the IgG 
antibody levels stabilized over time. IgG antibody levels were also found to double after 
the PCR resulted negative. [4] Another study found that the average levels of IgM and 
IgA antibodies increased within 6-8 days from the onset of symptoms. Compared to the 
IgM antibody, IgA antibody showed persistently higher levels for the whole observation 
period, with a peak level at 20-22 days. [5] The detection of the antibodies collectively at 
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the time when the PCR becomes negative implied that they may have a role in the clearance of the virus. [2] While one 
study linked the appearance of antibodies with the severity of the disease, another study revealed that it may be inde-
pendent of the clinical course of the disease. [6] It was also found that high antibody levels may help in the progression 
of the infection as high viral load lead to strong extra-follicular B cell stimulation leading to rapid antibody production 
which doesn’t follow the sequential change from IgM to IgG. Such antibodies stimulate cytokine storm which has been 
implicated in acute lung injury associated with COVID-19 infection. [6] Many patients were found to be seropositive 
within the course of illness for more than 30 days. [2] However, a negative serological test does not exclude COVID-19 
infection as many patients were found to be seronegative during the early course of the infection. [4] Hence the results 
of these serological assays may be inconclusive during the early course of the disease.
The CDC categorizes antibody tests into two broad categories: 1) Binding antibody detection tests and 2) neutralizing 
antibody tests. While the use of neutralizing antibody tests has not been approved by the US-FDA, the binding antibody 
tests are widely employed in the detection of the IgG and IgM antibodies. These tests detect the presence of different 
types of antibodies against different components of the SARS-CoV-2 virus using purified proteins of the virus. Specific 
reagents are used to identify individual antibody types such as IgG, IgM, and IgA. These tests are further classified into 
point-of-care tests (POC) such as lateral flow immunochromatography assays (LFIA) and laboratory-based tests such 
as Enzyme-linked immunosorbent assay (ELISA) and chemiluminescent assay (CIA). POC tests are performed at the 
time and place of patient care such as the patient’s bedside or the physician’s office. These tests use lateral flow devices 
to detect IgG or IgG and IgM or total antibody in serum, plasma, whole blood, saliva. While the POC tests can be per-
formed in a field setting, lab-based tests require trained laboratorians and a specialized setting. IgG/IgM rapid tests are 
the two available point of care, qualitative antibody detection tests. [1] 
The current recommendations by CDC heavily depend upon the use of reverse transcriptase polymerase chain reaction 
(RT-PCR) for the qualitative detection of SARS-CoV-2 viral nucleic acid for the diagnosis and the management of the 
COVID-19. In the wake of the increasing emergence of challenges and limitations of the molecular tests, the importance 
of rapid diagnostic antibody tests has increased, and their role is being rapidly explored. [7] In our review, we explore 
the role of the POC antibody tests.
Methods
For our article, literature contained in Google Scholar, PubMed,  and Embase, as well as websites for the Center for 
Disease Control (CDC) and the Infectious Diseases Society of America (IDSA) database, was searched using combina-
tions of keywords ‘SARS-CoV-2’, ‘coronavirus’, ‘COVID-19 pandemic’, ‘health care workers’, ‘molecular test’, ‘diagnos-
tic tests’, ‘serological tests’ and their variants. The articles used for the review were published within the last 6 months 
(December 2019 to June 2020).
Results
Seven studies were eligible for inclusion in this review. All the included studies used immunochromatography method 
of POC IgG/IgM antibody test. The tests were conducted on blood or plasma or serum samples. Spicuzza et al, Ying et 
al, Zhengtu et al, Dohla et al, and Choe et al used combined IgG/IgM antibody kit and divided patients in two groups. 
[8-12] One group had patients who tested positive for SARS-CoV-2 using RT-PCR while the second group had patients 
who were suspected of having COVID-19 infection, but tested negative on an RT-PCR. Hoffman et al conducted the 
study by dividing their patients in a similar manner, but they used rapid IgG-IgM detection test which detected IgG 
and IgM antibody separately. [13] While Xiang et also used rapid IgG-IgM antibody detection kit detecting the anti-
bodies separately, they tested patients diagnosed with a positive viral RT-PCR in both groups. [14] They tested one of 
the groups with laboratory-based ELISA antibody test while the other group was tested using the rapid IgG-IgM POC 
antibody test. These studies calculated the sensitivities and specificities of the test, which can be seen in Table 1.
ULJRI | https://doi.org/10.18297/jri/vol4/iss1/70 3
ULJRI The Role of Rapid Diagnostic Point of Care IgG/IgM Antibody Tests in the Diagnosis of SARS-CoV-2 Infection
S.no Author Title Result Summary
1 Spicuzza et al
Reliability and usefulness of a 
rapid IgM-IgG antibody test for 
the diagnosis of SARS-CoV-2 
infection: A preliminary report.
 Sample size-37           
Sensitivity=82.6%         
Specificity=92.8%
In patients presenting with a 
discrepancy between the clinical/
radiological feature and the molecular 
test, the rapid antibody detection might 
be an additional element helping the 
clinician to make a correct diagnosis
2 Xiang et al
Diagnostic Indexes of a Rapid 
IgG/IgM Combined Antibody 
Test for SARS-CoV-2
Sample size-179       
Sensitivity- 85% 
(77/90)       
 Specificity- 91% 
(8/89)
The sensitivity and specificity of the 
IgG/IgM combined test kit is adequate, 
with short turnaround time, no specific 
requirements for additional equipment 
or skilled technicians, all of these 
collectively contribute to its competence 
for mass testing. At the current stage, 
it cannot replace SARA-CoV-2 nucleic 
acid RT-PCR, but it can serve as a 
complementary option with RT-PCR.
3 Yan et al
Evaluation of Enzyme-linked 
Immunoassay and Colloidal 
Gold Immunochromatographic 
Assay kit for detection of 
novel coronavirus (SARS-
CoV-2) causing an outbreak of 
pneumonia (COVID 19)
Sample size-154              
Sensitivity- 82(75/91)     
Specificity- 100% 
(35/35)
Although ELISA and GICA are simple, 
fast, and safe, the results can be used 
for clinical reference
4 Hoffman et al
Evaluation of a COVID-19 IgM 
and IgG rapid test; an efficient 
tool for assessment of past 
exposure to SARS-CoV-2
Sample size - 153        
Sensitivity- Ig 
M: 69% (20/29)             
Ig G-99% (27/29)         
Specificity- Ig 
M-100% (124/124)         
Ig G- 99%(123/124)
The test is suitable for assessing 
previous virus exposure, although 
negative results may be unreliable 
during the first few weeks after infection.
5 Zhengtu et al
Development and clinical 
application of a rapid IgM-
IgG combined antibody test 
for SARS-CoV-2 infection 
diagnosis
Sample size-397           
Sensitivity- 
89% (352/397)             
Specificity- 91% 
(12/128) 
The IgM-IgG combined assay has better 
utility and sensitivity compared with a 
single IgM or IgG test. It can be used for 
the rapid screening of SARS-CoV-2
carriers, symptomatic or asymptomatic, 
in hospitals, clinics, and test laboratories
6 Dohla et al
Rapid point-of-care testing for 
SARS-CoV-2 in a community 
screening setting shows low 
sensitivity
Sample size-49                 
Sensitivity- 36.4%           
Specificity- 90% 
Rapid antibody test have low sensitivity 
and is not recommended for community 
screening.
7 Choe et al
Diagnostic performance of 
immunochromatography assay 
for
rapid detection of IgM and IgG 
in coronavirus disease 2019
 Sample size- 149           
Sensitivity- 93% 




COVID-19 IgG/IgM rapid test is a useful 
and practical diagnostic assay for 
practical diagnostic assay for detection 
of COVID-19, especially in the presence 
of IgM or IgG antibodies.
Table 1. Studies considered for our review.
Discussion
It was observed that the overall sensitivity and specificity of these antibody tests was high except for Dohla et al. The 
antibody tests also yielded high sensitivity and specificity for the detection of individual IgG/IgM antibodies. The re-
sults indicate that these tests could play a very important role in diagnosis of SARS-CoV-2 infection when used in con-
junction with the molecular tests. The rapid diagnostic POC test could be preferred over the laboratory-based antibody 
test. Hence, the rapid diagnostic IgG/IgM antibody tests can be used in conjunction with the molecular test. These 
tests are faster, less expensive, easy to use, accessible to staff without lab training and are higher specificity versus the 
laboratory-based antibody test. [4,2,15] These antibody tests have also been found to be beneficial in diagnosing pa-
tients with a prolonged clinical course. They can be used to diagnose patients with a prolonged course of illness, who 
get a false negative result on the PCR. [2] They can diagnose patients who have recovered from a prior asymptomatic 
infection. These asymptomatic patients may have a positive IgG, a negative IgM, a negative molecular test with no prior 
history of COVID-19 infection. [16] POC antibody tests can also be used for contact tracing, serological surveillance at 
local, regional, state, and national levels. They can identify possibly immune patients and individuals who could be a 
source of therapeutic or prophylactic neutralizing antibodies and vaccine trials. [15,17] However, the use of these assays 
cannot be used to determine immune status in individuals until the presence, durability and duration of immunity is 
established. [1]
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